



Figure



ნ ე ე



A Ipha-2a Mock HHK acid] g [n icotin ic <u>°</u> 軍王 HH -0.1 0 0 0

Aggregation Response

ntrolC

0

c id

4

ic o tin ic


Z


 $\infty$ 


Figure


Basal Nicotinic acid induced-IPs accumulation in 293 cells co-expressing hRUP25 and Gq∆Gi hRUP38+ Figure 4 hRUP25+ Gq∆Gi 一年前是此時時間 hRUP19+ Gq∆Gi Gq∆Gi 9009 1000 5000 4000 3000 2000 (cbm/well) Inositol phosphates

# Figure 5A hRUP25-CHO stable clone identified by anti-H immunofluorescence staining












forskolin stimulated cAMP accumulation in hRUP25-Nicotinic acid and nicotine induced-inhibition of CHO cell stable line #46 Figure 5B



accumulation following activation by nicotinic acid hRUP25 and mRUP25 inhibit TSHR induced-cAMP Figure 6



## hRUP25 and mRUP25 bind to nicotinic acid specifically and with high affinity Figure 7



# he rank order of potency of compounds on hRUP25 closely matches that of the pharmacologically defined nicotinic acid receptor Figure 8


			- EC 50 (µM)	
Compound	Adipocytes*	Spleen*	hRUP25†	hRUP25 (K,)‡
Nicotinic acid	1.42	0.703	0.04	0.14
Pyridazine-4-carboxylic acid	3.76	3.14	N.D.	2.19
Acipimox	10.3	95.9	2	2.68
3-Pyridine-acetic acid	16.4	21.8	n	1.64
Pyrazine-2-carboxylic acid	26	22	4	4.14
5-Methylnicotinic acid	30.2	30.0	7	3.58
5-Methylpyrazine-2-carboxylic acid	52.0	14.5	7	7.36
6-Methylnicotinic acid	72.6	53.7	34	21.95
Nicotinic acid-1-oxide	80.4	73.7	120	55.25
2-Hydroxynicotinic acid	132	N.D.	130	145.4
Furane-3-carboxylic acid	142	N.D.	110	130.6
Nicotinamide	>1000	>1000	>1000	128.2
N.D., not determined.				

<sup>\*</sup> From Lorenzen, A. et. al. Mol. Pharmacol. 59 (2):349-357, 2001.


<sup>†</sup> Arena data, inhibition of forskolin-induced cAMP production in hRUP25-CHO stable line #46.

<sup>‡</sup> Arena data, [3H]nicotinic acid radioligand binding assay on membranes derived from hRUP25-CHO stable line #46.


Nicotinic acid and related compounds inhibit isoprotereno induced lipolysis in rat epidimal fat derived adipocytes Figure 9A



Nicotinic acid dose-dependent inhibition of isoproterenol induced-lipolysis in rat, epidimal fat derived adipocytes Figure 9B



Dose-dependent inhibition of isoproterenol induced-lipolysis in human, subcutaneous-derived, primary adipocytes via nicotinic acid and P-3-T Figure 10



## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.